
Cardiomyopathy Therapies
Description
Global Cardiomyopathy Therapies Market to Reach US$3.4 Billion by 2030
The global market for Cardiomyopathy Therapies estimated at US$3.1 Billion in the year 2024, is expected to reach US$3.4 Billion by 2030, growing at a CAGR of 1.6% over the analysis period 2024-2030. Dilated Cardiomyopathy, one of the segments analyzed in the report, is expected to record a 1.9% CAGR and reach US$1.9 Billion by the end of the analysis period. Growth in the Hypertrophic Cardiomyopathy segment is estimated at 1.4% CAGR over the analysis period.
The U.S. Market is Estimated at US$835.4 Million While China is Forecast to Grow at 3.0% CAGR
The Cardiomyopathy Therapies market in the U.S. is estimated at US$835.4 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$625.0 Million by the year 2030 trailing a CAGR of 3.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.7% and 1.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.0% CAGR.
Global Cardiomyopathy Therapies Market - Key Trends and Drivers Summarized
Cardiomyopathy is a complex and heterogeneous group of heart muscle diseases that impair the heart`s ability to pump blood effectively. These conditions can be classified into several types, including dilated, hypertrophic, restrictive, and arrhythmogenic right ventricular cardiomyopathy. Each type has distinct etiologies, pathophysiologies, and clinical presentations, necessitating tailored therapeutic approaches. Current treatment options for cardiomyopathy range from pharmacological interventions such as beta-blockers, ACE inhibitors, and anticoagulants, to non-pharmacological strategies, including lifestyle modifications and the use of implantable devices like pacemakers and defibrillators. In severe cases, patients may require advanced therapies such as cardiac resynchronization therapy, ventricular assist devices, or even heart transplantation. Despite the variety of treatments available, managing cardiomyopathy remains challenging due to its progressive nature and the potential for sudden cardiac death.
Recent advancements in the understanding of molecular and genetic underpinnings of cardiomyopathy have paved the way for innovative therapeutic approaches. Gene therapy and molecular-targeted therapies are at the forefront of research, offering potential curative solutions for certain genetic forms of cardiomyopathy. For instance, CRISPR-Cas9 gene editing and RNA interference are being explored to correct or silence defective genes responsible for cardiomyopathy. Additionally, the development of novel pharmacological agents, such as myosin inhibitors and selective cardiac myosin activators, is aimed at directly modulating cardiac contractility and improving heart function. Stem cell therapy also holds promise, with ongoing clinical trials investigating its potential to regenerate damaged heart tissue and restore myocardial function. These cutting-edge therapies are complemented by advancements in diagnostic tools, including next-generation sequencing and advanced imaging techniques, which facilitate early and precise diagnosis, thereby enabling timely and targeted interventions.
The growth in the cardiomyopathy therapies market is driven by several factors. The rising prevalence of cardiovascular diseases, particularly in aging populations, has significantly increased the demand for effective cardiomyopathy treatments. Technological advancements in diagnostic and therapeutic modalities have expanded the range of available treatment options, making it possible to offer more personalized and effective care. Increased awareness and understanding of cardiomyopathy among patients and healthcare providers have led to earlier diagnosis and intervention, improving patient outcomes. Furthermore, substantial investments in research and development by pharmaceutical companies and academic institutions are accelerating the discovery and commercialization of novel therapies. Supportive government policies and favorable reimbursement frameworks in many regions are also playing a crucial role in making advanced treatments accessible to a broader patient population. Additionally, the integration of digital health technologies, such as remote monitoring and telemedicine, is enhancing patient management and adherence to therapy, thereby driving market growth. Collectively, these factors are fostering a dynamic and rapidly evolving market for cardiomyopathy therapies.
SCOPE OF STUDY:The report analyzes the Cardiomyopathy Therapies market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Disease Type (Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy, Other Disease Types)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 86 Featured) -
- Abbott Cardiovascular
- Alexion Pharmaceuticals, Inc.
- Astellas Pharma Inc.
- AstraZeneca Plc
- Bio-Rad Laboratories, Inc.
- Bristol Myers Squibb company
- Cardiol Therapeutics, Inc.
- Cipla Ltd
- Cytokinetics, Inc.
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Regeneron Pharmaceuticals, Inc.
- Roche Diagnostics (Schweiz) AG
- Tenaya Therapeutics
We`re transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.
The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.
Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
Table of Contents
- I. METHODOLOGY
- II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- Global Economic Update
- Cardiomyopathy Therapies – Global Key Competitors Percentage Market Share in 2025 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- Rising Prevalence of Cardiovascular Diseases Spurs Demand for Cardiomyopathy Therapies
- Technological Advancements in Diagnostic Modalities Propel Growth
- Gene Therapy and Molecular-Targeted Treatments Expand Addressable Market Opportunity
- Increased Awareness and Early Diagnosis Strengthen Business Case for Innovative Therapies
- Development of Novel Pharmacological Agents Generates New Market Opportunities
- Here`s How Advancements in Stem Cell Therapy Drive Market Dynamics
- Growing Focus on Personalized Medicine Drives Adoption of Tailored Treatment Approaches
- Integration of Digital Health Technologies Sustains Growth in Patient Management
- Expansion of Telemedicine Services Enhances Access to Cardiomyopathy Care
- Rising Geriatric Population Throws the Spotlight On Need for Comprehensive Cardiac Care
- Here`s the Story: Impact of Advanced Imaging Techniques on Early and Accurate Diagnosis
- Evolution of Multimodal Treatment Strategies Drives Comprehensive Patient Care
- Advances in Biomarker Discovery Generate Opportunities for Precision Medicine
- Trend towards Outpatient Cardiac Care Spurs Demand for Non-Invasive Therapies
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Cardiomyopathy Therapies Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 3: World Historic Review for Cardiomyopathy Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 4: World 15-Year Perspective for Cardiomyopathy Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for Dilated Cardiomyopathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 6: World Historic Review for Dilated Cardiomyopathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 7: World 15-Year Perspective for Dilated Cardiomyopathy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Hypertrophic Cardiomyopathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 9: World Historic Review for Hypertrophic Cardiomyopathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 10: World 15-Year Perspective for Hypertrophic Cardiomyopathy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 11: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 12: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 13: World 15-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- III. MARKET ANALYSIS
- UNITED STATES
- Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
- TABLE 14: USA Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 15: USA Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 16: USA 15-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2015, 2025 & 2030
- CANADA
- TABLE 17: Canada Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 18: Canada Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 19: Canada 15-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2015, 2025 & 2030
- JAPAN
- Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
- TABLE 20: Japan Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 21: Japan Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 22: Japan 15-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2015, 2025 & 2030
- CHINA
- Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
- TABLE 23: China Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 24: China Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 25: China 15-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2015, 2025 & 2030
- EUROPE
- Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
- TABLE 26: Europe Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 27: Europe Historic Review for Cardiomyopathy Therapies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 28: Europe 15-Year Perspective for Cardiomyopathy Therapies by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
- TABLE 29: Europe Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 30: Europe Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 31: Europe 15-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2015, 2025 & 2030
- FRANCE
- Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
- TABLE 32: France Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 33: France Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 34: France 15-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2015, 2025 & 2030
- GERMANY
- Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
- TABLE 35: Germany Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 36: Germany Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 37: Germany 15-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2015, 2025 & 2030
- ITALY
- TABLE 38: Italy Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 39: Italy Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 40: Italy 15-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2015, 2025 & 2030
- UNITED KINGDOM
- Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
- TABLE 41: UK Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 42: UK Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 43: UK 15-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2015, 2025 & 2030
- SPAIN
- TABLE 44: Spain Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 45: Spain Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 46: Spain 15-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2015, 2025 & 2030
- RUSSIA
- TABLE 47: Russia Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 48: Russia Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 49: Russia 15-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2015, 2025 & 2030
- REST OF EUROPE
- TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 51: Rest of Europe Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 52: Rest of Europe 15-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2015, 2025 & 2030
- ASIA-PACIFIC
- Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
- TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 54: Asia-Pacific Historic Review for Cardiomyopathy Therapies by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 55: Asia-Pacific 15-Year Perspective for Cardiomyopathy Therapies by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
- TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 57: Asia-Pacific Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 58: Asia-Pacific 15-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2015, 2025 & 2030
- AUSTRALIA
- Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
- TABLE 59: Australia Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 60: Australia Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 61: Australia 15-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2015, 2025 & 2030
- INDIA
- Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
- TABLE 62: India Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 63: India Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 64: India 15-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2015, 2025 & 2030
- SOUTH KOREA
- TABLE 65: South Korea Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 66: South Korea Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 67: South Korea 15-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2015, 2025 & 2030
- REST OF ASIA-PACIFIC
- TABLE 68: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 69: Rest of Asia-Pacific Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 70: Rest of Asia-Pacific 15-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2015, 2025 & 2030
- LATIN AMERICA
- Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
- TABLE 71: Latin America Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 72: Latin America Historic Review for Cardiomyopathy Therapies by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 73: Latin America 15-Year Perspective for Cardiomyopathy Therapies by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
- TABLE 74: Latin America Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 75: Latin America Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 76: Latin America 15-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2015, 2025 & 2030
- ARGENTINA
- TABLE 77: Argentina Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 78: Argentina Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 79: Argentina 15-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2015, 2025 & 2030
- BRAZIL
- TABLE 80: Brazil Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 81: Brazil Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 82: Brazil 15-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2015, 2025 & 2030
- MEXICO
- TABLE 83: Mexico Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 84: Mexico Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 85: Mexico 15-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2015, 2025 & 2030
- REST OF LATIN AMERICA
- TABLE 86: Rest of Latin America Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 87: Rest of Latin America Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 88: Rest of Latin America 15-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2015, 2025 & 2030
- MIDDLE EAST
- Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
- TABLE 89: Middle East Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 90: Middle East Historic Review for Cardiomyopathy Therapies by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 91: Middle East 15-Year Perspective for Cardiomyopathy Therapies by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
- TABLE 92: Middle East Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 93: Middle East Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 94: Middle East 15-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2015, 2025 & 2030
- IRAN
- TABLE 95: Iran Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 96: Iran Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 97: Iran 15-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2015, 2025 & 2030
- ISRAEL
- TABLE 98: Israel Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 99: Israel Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 100: Israel 15-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2015, 2025 & 2030
- SAUDI ARABIA
- TABLE 101: Saudi Arabia Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 102: Saudi Arabia Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 103: Saudi Arabia 15-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2015, 2025 & 2030
- UNITED ARAB EMIRATES
- TABLE 104: UAE Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 105: UAE Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 106: UAE 15-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2015, 2025 & 2030
- REST OF MIDDLE EAST
- TABLE 107: Rest of Middle East Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 108: Rest of Middle East Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 109: Rest of Middle East 15-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2015, 2025 & 2030
- AFRICA
- Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
- TABLE 110: Africa Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 111: Africa Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 112: Africa 15-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2015, 2025 & 2030
- IV. COMPETITION
Pricing
Currency Rates